Rein Therapeutics (RNTX) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed Rein Therapeutics (RNTX) over the past year, losing 4.4% versus a loss of 44.7%. Over five years, RNTX leads with a -96.2% price change compared with -96.9% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($70.6 million vs $68.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNTX | VRCA |
|---|---|---|
| Share price | $0.794 | $4.11 |
| Market cap | $68.50M | $70.60M |
| 1-day change | +3.21% | -1.67% |
| YTD return | -33.68% | -50.54% |
| 1-year return | -44.65% | -4.42% |
| 5-year return | -96.19% | -96.92% |
| EPS (TTM) | $-1.68 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.18 | $9.82 |
| 52-week low | $0.694 | $3.28 |
| Distance from 52-week high | -63.58% | -58.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +655.67% | +236.50% |
| Average volume | 435.29K | 63.33K |
| Shares outstanding | 86.27M | 17.18M |
| Employees | 10 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed RNTX by 40.2 percentage points over the past year.
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
RNTX vs VRCA FAQ
Which is bigger, Rein Therapeutics or Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $70.60M compared with $68.50M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, RNTX or VRCA?
VRCA returned -4.42% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Rein Therapeutics and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.